Loading
Life sciences · Journal article
Clinical Pharmacology & Therapeutics · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pregnancy is characterized by physiologic, metabolic, immunologic, and microbial adaptation. Medication use during pregnancy is common. Yet, therapeutic response often remains unpredictable because obstetric pharmacology has historically focused on pharmacokinetic changes while paying little attention to host-microbiome-drug interactions. Pharmacomicrobiomics, the study of bidirectional interactions between the microbiome and therapeutic agents, has emerged as an important frontier in precision medicine. Increasing evidence demonstrates that the maternal microbiome may influence drug bioavailability, metabolism, efficacy, toxicity, immune response, and placental signaling during pregnancy. Conversely, medications used in obstetric practice, including antibiotics, antiretrovirals, metformin, iron supplementation, and proton pump inhibitors, may reshape maternal microbial ecosystems with downstream implications for maternal-fetal health. Pregnancy introduces pharmacomicrobiomic complexity because the maternal gut, vaginal, and oral microbial communities evolve across gestation, while the placenta and fetus are exposed to microbial metabolites and microbe-associated signals without convincing evidence of stable resident microbiomes. Emerging data suggest that microbial composition may influence preterm birth, hypertensive disorders of pregnancy, gestational diabetes mellitus, obesity, fetal growth, immune development, and therapeutic responsiveness. This mini-review examines recent advances in obstetric pharmacomicrobiomics with emphasis on microbial regulation of drug metabolism, pregnancy-associated microbial remodeling, microbiome-mediated therapeutic variability, placental and fetal implications, and future translational applications. We propose that obstetric pharmacology is entering a systems biology era in which the maternal microbiome should be investigated as a potentially important determinant of therapeutic response rather than treated solely as a background physiologic variable. Integrating microbiome science into maternal-fetal therapeutics may ultimately improve individualized treatment strategies, drug development, and precision obstetric pharmacology.